Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
Organic growth amounted to 3.9%, of which volume accounted for 1.7% and price/mix 2.2%. Excluding restructuring, organic growth increased 4.9%.EBITA decreased 1% to SEK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback